2269 — WuXi Biologics (Cayman) Balance Sheet
0.000.00%
- HK$143.73bn
- HK$140.11bn
- CNY18.68bn
- 92
- 19
- 95
- 83
Annual balance sheet for WuXi Biologics (Cayman), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8,481 | 11,126 | 8,714 | 11,243 | 10,710 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,122 | 4,851 | 6,126 | 6,783 | 6,412 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 14,204 | 19,530 | 18,470 | 21,198 | 23,573 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 12,870 | 19,756 | 25,916 | 29,939 | 28,435 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 28,964 | 44,033 | 49,564 | 56,576 | 56,977 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,498 | 8,256 | 9,319 | 7,636 | 8,621 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8,399 | 11,754 | 14,517 | 16,244 | 15,158 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 20,564 | 32,279 | 35,047 | 40,332 | 41,819 |
| Total Liabilities & Shareholders' Equity | 28,964 | 44,033 | 49,564 | 56,576 | 56,977 |
| Total Common Shares Outstanding |